Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697962 | 0.88 | ALDH1A1 (0.38) | ALDH1A1PKMNAPRTSIRT6 | |
| SCHEMBL1697956 | 0.87 | DAO (0.42) | DAOMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1698121 | 0.84 | CSNK2A2 (0.43) | KMT2AALDH1A1KDM4EPKML3MBTL1 | |
| SCHEMBL1697997 | 0.74 | MEN1 (0.42) | DAOMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1697868 | 0.73 | GPR35 (0.41) | DAOMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL30806841 | 0.72 | ALDH1A1 (0.53) | DAOMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL18249385 | 0.72 | ALDH1A1 (0.53) | DAOMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1697903 | 0.72 | CSNK2A2 (0.43) | ALDH1A1KDM4EPKMMAPTCCNC | |
| SCHEMBL31605037 | 0.72 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL16942514 | 0.72 | ALDH1A1 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562018-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Biogen MA Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026061-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-2576566-B1 | THIENO(2,3B)PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | MERCK SHARP & DOHME (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2576566-B1 | THIENO(2,3B)PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | MERCK SHARP & DOHME (NL) | 2015-10-28 | — | — | EP | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| US-8669256-B2 | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity | MERCK SHARP & DOHME B.V. (NL) | 2014-03-11 | — | — | US | disclosed |
| EP-2576566-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | MSD Oss B.V. (NL) | 2013-04-10 | — | — | EP | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2013-03-28 | — | — | US | disclosed |
| WO-2011147764-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | N.V. ORGANON (NL) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147764-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS | N.V. ORGANON (NL) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079341-A1 | THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | DAO 3820/4885MEN1 1820/4885KMT2A 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.